|
| Status |
Public on Jun 26, 2024 |
| Title |
6_EV_DX_DMSO_C |
| Sample type |
SRA |
| |
|
| Source name |
HT1376
|
| Organism |
Homo sapiens |
| Characteristics |
treatment1: DMSO
treatment2: with Dox
cell type: HT1376-TetOn
|
| Treatment protocol |
T1376-TetON control cells and a clonal HT1376-TetON-ARID1A cell line were induced with 50 ng/ml doxycycline for 24 hours and then treated for 4 days with DMSO or 250 nM CPI-0209.
|
| Growth protocol |
Cells were grown in MEM(Earl's Salts) + 10% FBS, 1% Non-essential AA, 1 mM NaPyruvate, 1% Pen/Strep
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was extracted with Trizol, in accordance with the manufacturer’s protocol.
Sequencing libraries were constructed using the Illumina TruSeq RNA Sample Preparation Kit (v2). The resulting libraries were sequenced on an Illumina HiSeq 4000, with 9 samples multiplexed per lane. 2x150 base pair paired-end reads using the Illumina TruSeq strand specific protocol, for an expected 40 million reads per sample.
|
| |
|
| Library strategy |
RNA-Seq |
| Library source |
transcriptomic |
| Library selection |
cDNA |
| Instrument model |
Illumina HiSeq 4000 |
| |
|
| Data processing |
Sequencing reads were mapped to the genome using STAR v2.7.3a with default settings
The transcript and gene read count quantification were performed using RSEM v1.3.1 with default settings
Genome_build: hg38
Supplementary_files_format_and_content: txt file: raw counts
|
| |
|
| Submission date |
Jun 08, 2021 |
| Last update date |
Jun 26, 2024 |
| Contact name |
Patrick Trojer |
| E-mail(s) |
patricktroj@gmail.com
|
| Organization name |
Constellation Pharmaceuticals
|
| Street address |
215 First Street, Suite 200
|
| City |
Cambridge |
| State/province |
Massachusetts |
| ZIP/Postal code |
02142 |
| Country |
USA |
| |
|
| Platform ID |
GPL20301 |
| Series (2) |
| GSE176358 |
Transcriptomic change of ARDI1A mutant bladder cancer cell line treated with CPI-0209 or induced ARID1A expression |
| GSE176493 |
Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma |
|
| Relations |
| BioSample |
SAMN19605093 |
| SRA |
SRX11091717 |
